Atea Pharmaceuticals (AVIR) Free Cash Flow (2019 - 2026)

Atea Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$46.4 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 51.79% year-over-year to -$46.4 million; the TTM figure through Mar 2026 stood at -$147.9 million (down 17.17% YoY), while the FY2025 annual figure was -$132.0 million, up 2.56% from the prior year.
• Free Cash Flow was -$46.4 million for Q1 2026 at Atea Pharmaceuticals, down from -$28.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$16.1 million in Q2 2023 to a low of -$59.7 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$30.7 million across 5 years, with a median of -$29.8 million in 2023.
• Biggest YoY gain for Free Cash Flow was 71.43% in 2022; the steepest drop was 254.64% in 2022.
• A 5-year view of Free Cash Flow shows it stood at -$21.5 million in 2022, then fell by 1.34% to -$21.8 million in 2023, then slumped by 39.22% to -$30.4 million in 2024, then advanced by 7.15% to -$28.2 million in 2025, then tumbled by 64.37% to -$46.4 million in 2026.
• The last three Free Cash Flow figures came in at -$46.4 million (Q1 2026), -$28.2 million (Q4 2025), and -$40.4 million (Q3 2025), per Business Quant data.